Advances in Hyperkalemia Management: Implications for Patients and Providers

Released On
September 30, 2019

Expires On
September 30, 2020

Media Type

Completion Time
60 minutes


Family Physicians, Primary Care Physicians, Nurse Practitioners/Physician Assistants, Hospitalists, Nephrologists, Cardiologists

Scroll to the Bottom of this Information to Begin this Course

Jointly provided MedChi, The Maryland State Medical Society and Rockpointe.


This program is supported by an unrestricted educational grant from AstraZeneca.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Physicians — ABIM MOC points

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for physicians, hospitalists, nephrologists, and cardiologists involved in the management and education of adults with or at risk for hyperkalemia.

Program Overview

Conventional treatment of hyperkalemia is restricted by adverse events, as well as a dearth of evidence supporting clinical use (specifically with sodium polystyrene sulfonate). For medication-induced hyperkalemia, treatment involves a dose decrease or discontinuation of the offending agent (usually a renin-angiotensin-aldosterone system inhibitor [RAASI]); however, this often prevents patients from receiving appropriate guideline-directed management. Recent research has led to the development of two novel potassium binders with good safety profiles that allow patients to maintain or increase the use of RAASIs for cardio- and reno-protection.

This CME activity, Advances in Hyperkalemia Management: Implications for Patients and Providers, will help participating clinicians identify those patient populations most likely to present with or develop hyperkalemia, and utilize the appropriate conventional and/or novel agents to correct subacute hyperkalemia.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Compare and contrast safety and efficacy data on novel and conventional agents for correcting subacute/chronic hyperkalemia
  • Identify patient populations likely to present with or develop hyperkalemia
  • Incorporate novel agents for correcting subacute hyperkalemia into patient care plans


Javed Butler, MD, MPH, MBA

Professor and Chairman
Department of Medicine
University of Mississippi
Jackson, MS

Biff F. Palmer, MD

Professor of Internal Medicine
Distinguished Teaching Professor
University of Texas Southwestern Medical Center
Dallas, TX

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of MedChi, The Maryland State Medical Society, and Rockpointe. MedChi is accredited by the ACCME to provide continuing medical education for physicians.

For information about accreditation of this activity, please email:

Credit Designation

MedChi designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ABIM MOC Designation Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through MedChi’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

Disclosures of Conflicts of Interest

MedChi, The Maryland State Medical Society, (MedChi) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by MedChi are required to disclose any relevant financial relationships with any commercial interest to MedChi as well as to learners. All conflicts of interest are identified and resolved by MedChi in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external reviewer to assure objectivity and that the activity is free of commercial bias.

Steering Committee

The steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Javed Butler, MD, MPH, MBA: Consultant/Independent Contractor: Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CVRx, G3 Pharmaceutical, Innolife, Janssen, LinaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche, Sanofi, V-Wave Limited, Vifor

Biff F. Palmer, MD: Nothing to disclose

Non-faculty Content Contributor

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Nicolle Rochino, PharmD, RPh; Blair St. Amand; Frank C. Berry; Steven F. Crawford, MD: Nothing to disclose

Instructions for Participation and Credit

There is no fee for this educational activity. In order to receive credit, you must watch the webcast, pass the post-test with a score of 67% or greater, and complete the evaluation. You will have multiple opportunities to take and pass the post-test.

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser, this list includes the versions of Mircrosoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player.

Disclosure of Unlabeled Use

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.